First Results from CORE-008 Cohort CX- Study of Intravesical Cretostimogene Grenadenorepvec with Gemcitabine in Patients with High-Risk BCG-Exposed or BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

Saturday, May 16, 2026 4:25 PM to 4:30 PM · 5 min. (America/New_York)
Ballroom A
Detail
Oncology: General

Information

Of Interest To
Advanced Practice Providers (APP)

Log in

See all the content and easy-to-use features by logging in or registering!